Navigation Links
Treatment Resistant Tumors Can Be Targeted Better Using Botox

Botox, commonly used for cosmetic treatment may play an important role in enhancing the outcome of chemotherapy and radiotherapy, employed in cancer treatment. // Botox is a derivative of Botulinum toxin, a naturally occurring chemical known to cause intestinal poisoning.

The toxin has numerous clinical applications such as relieving facial spasms, strabismus and treating muscle hyperactivity. The toxin acts by blocking release of acetylcholine and norepinephrine (neurotransmitters).

It is hypothesized that this neurotransmitter release inhibition could inhibit neuromuscular contraction of blood vessels that supply the tumor. This could eventually pave way for enhanced tumor perfusion, allowing effective delivery of cytotoxic drugs and oxygen (improves tumor response to radiotherapy) supplied to the tumor.

To verify the above hypothesis, Dr. Bernard Gallez and his research team injected Botulinum neurotoxin (Type A) into mouse tumors. As expected, the vascular architecture of the tumor opened, destroying the previously resistant cancer cells. The study is the first of its kind to test the use of Botox as an adjuvant in the effective treatment of resistant tumors.

In addition, pre-treatment with Botox delayed further growth of the tumor and promoted apoptosis, that could enhance the clinical outcome of cancer treatment. Based on further research in the same direction, it might even be possible to overcome drug resistance or reduce standard radiotherapy and chemotherapy dosages, thereby eliminating the associated side effects.

Until now, much of cancer treatment has been focused towards starving the tumor of its blood supply. This new approach, targeted at enhanced blood supply for effective delivery of chemotherapeutic agents and radiation represents a new dimension of cancer research.

'Tumor vasculature is targeted by several advanced anti-cancer approaches that may appear contradic tory. Anti-angiogenesis and anti-vascular targeting are methods aimed at destroying the vessels that feed tumors, thereby depriving them of oxygen and nutrients. In contrast, pro-vascular approaches increase tumor perfusion and oxygenation temporarily,' concluded Dr. Gallez.


'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... ... Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and funding ... randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre ... live with dental fear and require sedation to receive dental care. The doctors offer ... various procedures, from hygienic cleanings to oral surgery, at their dental office in Vancouver. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring ... birth defects research related to Zika virus during pregnancy, as well as other ... this important science. , The Teratology Society is an international ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider ... care management module. Using this new feature, sleep physicians can now predict the ... continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology: